Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Petrelintide Phase 2 ZUPREME-1 topline data conference call (March 2026)
20 slides from Zealand Pharma A/s's conference presentation, Mar 5, 2026
Slide 1: Petrelintide Topline data Phase 2 ZUPREME-1 trial
Petrelintide Topline data Phase 2 ZUPREME-1 trial March 5, 2026 1
Slide 2: Agenda
1 Opening remarks Adam Steensberg, CEO Topline data 2 David Kendall, CMO Phase 2 ZUPREME-1 trial Agenda 3 Concluding remarks Adam Steensberg, CEO Adam Steensberg, CEO 4 Q&A David Kendall, CMO Henriette Wennicke, CFO 2
Slide 3: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 4: Opening remarks: Phase 2 ZUPREME-1 topline data
Opening remarks: Phase 2 ZUPREME-1 topline data Adam Steensberg, CEO 4
Slide 5: Real world data reveal a major gap in current obesity care
Real world data reveal a major gap in current obesity care Low treatment penetration Obesity needs new drug classes Desired weight loss contradicts ~3-5% of eligible patients in the 1 class available today vs. +8 Weight loss Olympics U.S. on pharmacotherapy1 classes for other chronic diseases 1 in 5
Slide 6: ZUPREME-1 data reinforce the potential of petrelintide to close that gap
ZUPREME-1 data reinforce the potential of petrelintide to close that gap Excellent safety and tolerability profile, comparable to placebo Redefining weight Double-digit body weight loss sustained management experience through week 42, suggesting the potential for continued weight loss with longer tr
Slide 7: Topline data Phase 2 ZUPREME-1 trial
Topline data Phase 2 ZUPREME-1 trial David Kendall, CMO 7
Slide 8: Amylin and GLP-1 exert distinct physiological and potentially distinct pharmacological effects
Amylin and GLP-1 exert distinct physiological and potentially distinct pharmacological effects Amylin GLP-1 Increases satiety1,2 Reduces appetite7 Effect on food intake Smaller meals, prolonged fullness6 Fewer meals, less food-seeking7 Leptin sensitivity Restores leptin responsiveness1,2 Minimal or
Slide 9: Trial design: Petrelintide ZUPREME-1 trial
Trial design: Petrelintide ZUPREME-1 trial A randomized, double-blind, placebo-controlled, Phase 2 dose-finding trial with petrelintide Dose Safety escalation follow-up Primary endpoint: • Percentage change in body weight Petrelintide dose group 5 from baseline to Week 28 Petrelintide dose group 4 S
Slide 10: Baseline characteristics were balanced across dose cohorts
Baseline characteristics were balanced across dose cohorts BMI Gender Weight Body Mass Index Age 53% of participants Mean 107 kg Mean 37 kg/m2 Mean 47 years were female Source: Data on file. 10
Slide 11: Petrelintide demonstrated robust, clinically meaningful weight reduction across all doses
Petrelintide demonstrated robust, clinically meaningful weight reduction across all doses Change in body weight (%) from baseline at week 42, efficacy estimand Petrelintide Petrelintide Petrelintide Petrelintide Petrelintide Placebo DG1 DG2 DG3 DG4 DG5 N=81 N=79 N=81 N=83 N=79 N=82 -1.7% -8.7% -9.2%
Slide 12: Sustained double-digit weight loss with multiple levers to optimize trial conditions
Sustained double-digit weight loss with multiple levers to optimize trial conditions for greater efficacy Change in body weight (%) from baseline • Body weight reduction continued through week 42, suggesting at week 42, efficacy estimand the potential for continued weight loss with longer treatment
Slide 13: Petrelintide demonstrated a potential best-in-class gastrointestinal tolerability profile
Petrelintide demonstrated a potential best-in-class gastrointestinal tolerability profile GI AEs largely comparable to placebo Pbo-adj. % of Pbo-adj. % of Pbo-adj. % of Pbo-adj. % of participants with participants with participants with participants with 20% nausea vomiting diarrhea constipation 18%
Slide 14: Treatment persistence supported by placebo-like discontinuation rates
Treatment persistence supported by placebo-like discontinuation rates Treatment discontinuation rate due to AEs Treatment discontinuation rate due to GI AEs 20% 20% 15% 15% 10% 10% 4.9% 4.5% 4.8% 5% 5% 1.5% 0.0% 0.0% 0% 0% Placebo Petrelintide Petrelintide Placebo Petrelintide Petrelintide N=81 Acro
Slide 15: Sustained, double-digit weight loss with a tolerability profile comparable to placebo
Sustained, double-digit weight loss with a tolerability profile comparable to placebo Efficacy • Up to 10.7% mean weight loss at week 42 versus 1.7% for placebo; further weight loss expected over time • Nearly 100% of participants on petrelintide achieved weight reduction • Efficacy influenced by tr
Slide 16: Concluding remarks
Concluding remarks Adam Steensberg, CEO 16
Slide 17: Petrelintide has the potential to establish a new treatment paradigm for chronic weight management
Petrelintide has the potential to establish a new treatment paradigm for chronic weight management ILLUSTRATIVE Clinically meaningful weight reduction Placebo-like tolerability Sustained, double-digit weight loss with Excellent tolerability profile, comparable multiple levers to enhance efficacy in
Slide 18: Shared commitment to redefine chronic weight management
Shared commitment to redefine chronic weight management • Equal partnership with co-development and co-commercialization for the petrelintide franchise • Strong financials, including 50/50 profit sharing for petrelintide and petrelintide/CT388 in U.S. and Europe • Zealand Pharma scaling alongside Ro
Slide 19: 2026: Most defining and catalyst-rich year yet
2026: Most defining and catalyst-rich year yet NON-EXHAUSTIVE Petrelintidea Survodutideb Building the pipeline (amylin analog) (GCGR/GLP-1R) of the future ✓ Results from Ph2 ZUPREME-1 Results from Ph3 obesity ZP9830 (Kv1.3) program Results from Ph1a SAD and MAD, and clinical advancement Results from
Slide 20: Q&A
Q&A Adam Steensberg David Kendall Henriette Wennicke Chief Executive Chief Medical Chief Financial Officer Officer Officer 20
Zealand Pharma — Petrelintide Phase 2 ZUPREME-1 topline data conference call (March 2026) on 6ix